Aurinia Pharmaceuticals
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 300
- Market Cap
- $962.3M
- Introduction
Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
LUPKYNIS-Based Triple Therapy Shows Superior Proteinuria Reduction in Lupus Nephritis Patients
New analysis of Phase 3 AURORA 1 study reveals that LUPKYNIS-based triple immunosuppressive therapy achieved significantly higher rates of low proteinuria targets compared to standard therapy in lupus nephritis patients.
Lupus Nephritis Market Expected to Grow as Novel Therapies Enter Clinical Trials
The global lupus nephritis market is projected to grow significantly by 2034, with the United States accounting for over 80% of the current $1.12 billion market share across major regions.
Aurinia Pharmaceuticals Restructures, Cutting 45% of Workforce to Focus on Lupkynis and AUR200
Aurinia Pharmaceuticals is reducing its workforce by 45% to save over $40 million annually, streamlining operations to focus on key assets.
Lupkynis (Voclosporin) Approved in Japan for Lupus Nephritis Treatment
The Japanese Ministry of Health, Labour, and Welfare approved Lupkynis (voclosporin) in combination with mycophenolate mofetil for treating lupus nephritis.
Aurinia Pharmaceuticals Initiates Phase Ia Trial of AUR200 for Autoimmune Diseases
Aurinia Pharmaceuticals has dosed the first subject in a Phase Ia trial of AUR200, an IgG4 Fc-fusion protein, for autoimmune diseases.
FDA Updates LUPKYNIS® Label with Three-Year Data and Modified Kidney Function Monitoring Guidelines for Lupus Nephritis
The FDA has updated the label for LUPKYNIS® (voclosporin) to include three-year data from the AURORA 2 extension study, demonstrating sustained complete renal response in patients with lupus nephritis (LN).